Johnson & Johnson is a multinational company that makes medicines, medical devices, and health products. Its recent disclosed lobbying relates to the 340B Drug Pricing Program, a federal program that affects drug prices for certain hospitals and clinics, and to Medicare and Medicaid issues. The filings show one report with no spending reported and that it used the firm Forbes-Tate.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
CYNTHIA BROWN
The latest disclosures for this client.
FORBES-TATE
RRThe entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
This client's filings do not yet disclose named government entities.
FORBES-TATE
ELIZABETH GREER
FORBES-TATE
mr MICHAEL ALEXANDER WILLIAMS
FORBES-TATE